Ranimustine

Summary

Ranimustine (CHEMBL2105348) is a phase-3 clinical-stage small molecule (ATC L01AD07); indicated across 2 conditions including neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01AD07
• Indications: 2 conditions
• Chemistry: 327.72 Da · C10H18ClN3O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105348
Name	Ranimustine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	71741
ATC	L01AD07
Molecular formula	C10H18ClN3O7
Molecular weight	327.72
InChIKey	AHHFEZNOXOZZQA-ZEBDFXRSSA-N

SMILES: CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CNC(=O)N(CCCl)N=O)O)O)O

IUPAC name: 1-(2-chloroethyl)-1-nitroso-3-[[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]urea

Also known as: Cymerin, NSC-270516, Ranimustina, Ranimustine, RANIMUSTINE

Patent coverage: 7,079 distinct patent families (27,253 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).